Search for: All records

Socially assistive robots can be used as therapeutic technologies to address depression symptoms. Through three sets of workshops with individuals living with depression and clinicians, we developed design guidelines for a personalized therapeutic robot for adults living with depression. Building on the design of Therabot™, workshop participants discussed various aspects of the robot’s design, sensors, behaviors, and a robot connected mobile phone app. Similarities among participants and workshops included a preference for a soft textured exterior and natural colors and sounds. There were also differences – clinicians wanted the robot to be able to call for aid, while participants with depression differed in their degree of comfort in sharing data collected by the robot with clinicians. 

Deploying socially assistive robots (SARs) at home, such as robotic companion pets, can be useful for tracking behavioral and health-related changes in humans during lifestyle fluctuations over time, like those experienced during CoVID-19. However, a fundamental problem required when deploying autonomous agents such as SARs in people’s everyday living spaces is understanding how users interact with those robots when not observed by researchers. One way to address that is to utilize novel modeling methods based on the robot’s sensor data, combined with newer types of interaction evaluation such as ecological momentary assessment (EMA), to recognize behavior modalities. This paper presents such a study of human-specific behavior classification based on data collected through EMA and sensors attached onboard a SAR, which was deployed in user homes. Classification was conducted using generative replay models, which attempt to use encoding/decoding methods to emulate how human dreaming is thought to create perturbations of the same experience in order to learn more efficiently from less data. Both multi-class and binary classification were explored for comparison, using several types of generative replay (variational autoencoders, generative adversarial networks, semi-supervised GANs). The highest-performing binary model showed approximately 79% accuracy (AUC 0.83), though multi-class classification across all modalities only attained 33% accuracy (AUC 0.62, F1 0.25), despite various attempts to improve it. The paper here highlights the strengths and weaknesses of using generative replay for modeling during human–robot interaction in the real world and also suggests a number of research paths for future improvement. 

Artificial Intelligence (AI)-driven Digital Health (DH) systems are poised to play a critical role in the future of healthcare. In 2021, $57.2 billion was invested in DH systems around the world, recognizing the promise this concept holds for aiding in delivery and care management. DH systems traditionally include a blend of various technologies, AI, and physiological biomarkers and have shown a potential to provide support for individuals with various health conditions. Digital therapeutics (DTx) is a more specific set of technology-enabled interventions within the broader DH sphere intended to produce a measurable therapeutic effect. DTx tools can empower both patients and healthcare providers, informing the course of treatment through data-driven interventions while collecting data in real-time and potentially reducing the number of patient office visits needed. In particular, socially assistive robots (SARs), as a DTx tool, can be a beneficial asset to DH systems since data gathered from sensors onboard the robot can help identify in-home behaviors, activity patterns, and health status of patients remotely. Furthermore, linking the robotic sensor data to other DH system components, and enabling SAR to function as part of an Internet of Things (IoT) ecosystem, can create a broader picture of patient health outcomes. The main challenge with DTx, and DH systems in general, is that the sheer volume and limited oversight of different DH systems and DTxs is hindering validation efforts (from technical, clinical, system, and privacy standpoints) and consequently slowing widespread adoption of these treatment tools.